Compare KRMD & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRMD | IGI |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 98.1M |
| IPO Year | N/A | N/A |
| Metric | KRMD | IGI |
|---|---|---|
| Price | $6.10 | $16.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.88 | N/A |
| AVG Volume (30 Days) | ★ 186.6K | 33.9K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.79% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | N/A |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $15.13 |
| 52 Week High | $6.61 | $17.79 |
| Indicator | KRMD | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 54.71 |
| Support Level | $5.48 | $16.33 |
| Resistance Level | $6.61 | $16.59 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 53.94 | 76.95 |
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.